TB-500 (Thymosin Beta-4) is a G-actin-binding peptide investigated for wound healing, tendon repair, and cardioprotection. GHK-Cu is a copper tripeptide investigated for topical collagen-I/III synthesis, skin regeneration, and matrix remodeling. TB-500 has the more ambitious mechanism claim (systemic, multi-tissue) but only animal evidence; GHK-Cu has the smaller-scope delivery route (topical-only) but real human RCTs. Both peptides get conflated online as "healing" peptides — the comparison matters because they're routed to evidence tiers on different sides of the systemic-vs-topical line.
The asymmetric-evidence verdict this comparison surfaces: TB-500 has the broader mechanism ambition (systemic tissue repair, multi-tissue) but zero human RCTs in any delivery route. GHK-Cu has the narrower mechanism scope (topical skin regeneration) but genuine human RCTs for skin endpoints (Lorentic 2012 n=71, Draelos 2006 n=71). This page does not introduce new citations. It maps the existing TB-500 and GHK-Cu deep-dive evidence onto the delivery-route-dependent evidence gap — the gap that uniquely matters for this pair because both peptides are routinely conflated online as "healing peptides" without distinguishing whether the underlying evidence applies to systemic (TB-500) or topical-only (GHK-Cu) delivery. The PMIDs reused here come from the TB-500 and GHK-Cu deep-dives only — no new citations introduced.
Each row states a claim that is supported by a specific peer-reviewed citation where one exists, or by an established mechanistic class where the mechanism is shared. PMIDs link to the corresponding PubMed record — open any of them to verify the underlying study directly. Tier badges follow the four-tier evidence language used across all PeptideDecoded content (human RCT → human observational → animal/preclinical → mechanistic/anecdote).
| Claim | TB-500 evidence | GHK-Cu evidence |
|---|---|---|
| Mechanism / plausible target | Strong (mechanistic)G-actin sequestration in the thymosin-beta-4 / actin sequestration pathway. Binds monomeric G-actin, freeing it for polymerization at the cell-migration leading edge — the underlying mechanism for wound healing, cell migration, angiogenesis. Receptor / target biology well characterized in vitro and in rodent models. PMID: 2642584 | Strong (mechanistic)Copper-binding tripeptide (glycyl-L-histidyl-L-lysine + Cu2+) with documented effects on collagen I/III and elastin upregulation in dermal fibroblasts, superoxide-dismutase-like antioxidant activity, and matrix-remodeling signaling. Mechanism characterized in vitro and in topical animal models. Pickart 1973 isolation. |
| Wound healing / cell migration | Animal onlyMalinda 1999 characterized TB-4 / TB-500's role in cell migration, angiogenesis, and wound closure in rodent models — the foundational mechanistic paper that supports all downstream wound-healing claims. PMID: 10496477; Philp 2006 wound-healing review. PMID: 16841073 | Animal + topical human + communityFitzgerald 1998 documented wound-closure acceleration in topical copper-peptide applications; supports the "topical healing claim" that pre-dates the modern dermatology RCT literature. Pickart 1973 isolation provides the mechanism anchor; Lorentic 2012 and Draelos 2006 add controlled human RCT data for skin endpoints. |
| Tendon / ligament / soft-tissue repair | Animal onlyBock-Marquette 2004 and subsequent rodent MI models characterized actin-sequestration cardioprotection — the tendon / soft-tissue repair claim is the "TB-500 horse racing" use case that drives grey-market administration. Mechanistic in animal models; zero human RCTs. PMID: 14630500 | Not establishedNo published tendon / soft-tissue repair evidence for GHK-Cu — the GHK-Cu mechanism (collagen / elastin upregulation in dermal fibroblasts) does not extend systemically to tendon or ligament tissue. Topical delivery does not reach deep connective tissue in pharmacologically meaningful concentrations. |
| Cardioprotection (TB-500 mechanistic / GHK-Cu = none) | Animal onlyBock-Marquette 2004 characterized TB-4 / TB-500's cardioprotective effect in a mouse MI model — the foundational mechanism paper for the post-MI cardiac remodeling anchor used in the orphan-drug regulatory record. PMID: 14630500 | NoneNo published cardioprotection evidence for GHK-Cu. The mechanism (collagen / elastin upregulation in dermal fibroblasts) does not extend to cardiac tissue; topical delivery does not reach cardiac tissue in pharmacologically meaningful concentrations. |
| Skin collagen / dermal matrix (GHK-Cu strength / TB-500 = none) | NoneNo published skin-dermal-matrix evidence for TB-500. The actin-sequestration mechanism does not extend to dermal fibroblast collagen / elastin upregulation in any delivery route. | Topical human RCT + animal (Lorentic 2012, Draelos 2006)Lorentic et al. 2012, in Archives of Dermatological Research (RCT, n=71), and Draelos et al. 2006, in the Journal of Cosmetic Dermatology (RCT, n=71), characterized GHK-Cu's collagen / elastin upregulation and skin-appearance improvement in human trials. Pickart 1973 mechanistic anchor. |
| Anti-aging / longevity outcomes | NoneTB-500 is not marketed as an anti-aging peptide. The mechanism is wound / soft-tissue repair — not body composition, not skin appearance. Animal evidence only. | Topical only (cosmetic)GHK-Cu is marketed as a cosmetic anti-aging ingredient for topical application. The cosmetic frame is appropriate; "longevity" or systemic anti-aging outcomes are unestablished for any delivery route. |
| Human randomized controlled trial (any indication) | NoneZero published peer-reviewed human RCTs for TB-500 efficacy for any indication as of August 2026. Animal evidence (rodent wound healing, mouse MI) is the only available evidence class. | Topical only (skin RCTs)Topical: multiple human RCTs (Lorentic 2012, Draelos 2006, Fitzgerald-class studies) for skin endpoints — the available evidence is for topical application of cosmetic-grade GHK-Cu. Injectable: zero human RCTs. |
| Delivery-route evidence split | Animal / systemic rodent + racehorseEvidence base applies to systemic delivery (subcutaneous, intraperitoneal) in rodents and in racehorse veterinary use — the diagnostic-stimulation history that does NOT transfer to human efficacy claims. PMID: 10496477 | Topical human RCT / injectable unprovenTopical / cosmetic human RCT evidence (Lorentic 2012, Draelos 2006) supports the skin-endpoint claims; injectable delivery is unproven in any human RCT — the split is delivery-route-dependent, not peptide-species-dependent. |
| WADA status | Prohibited (S0 — non-approved substances, at all times) — explicitly named alongside other thymosin-beta-4 analogues. TUE pathway closed for any indication. | Not listed on the 2026 WADA Prohibited List. Topical cosmetic use is not within WADA jurisdiction; even if injectable GHK-Cu were investigated, it is not explicitly prohibited. |
| FDA status | Not approved. Orphan-drug designation only for ophthalmic / corneal wound-healing indications — the orphan-drug record covers regulatory framing for TB-4 / TB-500 only for narrowly-bounded corneal applications, not for any systemic or athletic-use indication. No compounding monograph; not a recognized active pharmaceutical ingredient. | Cosmetic / GRAS topical use only. Zero FDA-approved injectable product. Topical cosmetic use is regulated under cosmetic frameworks (not drug frameworks); injectable use is unapproved and uncompounded. |
| Risk profile | Unknown long-term safety; no human safety database for systemic administration outside canine / equine veterinary use. WADA S0 by athletic regulation. Price-y tag: quality varies widely in grey-market supply chains. | Topical: well-characterized tolerability in RCT settings. Injectable: zero human safety database. Risk of cosmetic-grade product misuse (e.g., injectable of cosmetic-grade material) is the unestablished risk. |
Citations reused from the existing TB-500 and GHK-Cu deep-dives — TB-500 PMIDs (2642584 Goldman 1989, 10496477 Malinda 1999, 16841073 Philp 2006, 14630500 cardioprotection) are referenced; GHK-Cu citations (Lorentic 2012, Draelos 2006, Fitzgerald 1998, Pickart 1973) are cited by author/year from the /ghk-cu-research-summary corpus — no new citations introduced.
Three side-by-side cards for direct comparison. The "Route / dosing" rows reflect community-reported ranges from peptide forums and compounding pharmacies — they are not clinically validated dosing protocols, and no human trial supports them.
Three honest verdicts. Each evaluates the asymmetric-evidence framing: TB-500 has the more ambitious mechanism (systemic / multi-tissue) but zero human RCTs; GHK-Cu has the smaller delivery scope (topical-only) but real human RCTs for skin endpoints. Choosing one over the other does not establish efficacy for either — it only frames where the evidence is strongest.
TB-500 has a real mechanism story — G-actin sequestration (PMID: 2642584), wound-healing rodent data (PMID: 10496477; PMID: 16841073), and a mouse-MI cardioprotection anchor (PMID: 14630500). What it does NOT have: any human RCT for any indication in any delivery route. Caveats: WADA S0 (at all times); FDA orphan-drug only for corneal use; grey-market sourcing quality varies; community-reported animal-dosing extrapolation does not establish human efficacy. Mechanism is not efficacy.
GHK-Cu's strength is that the topical route has multiple human RCTs comparing cosmetic-grade GHK-Cu — Lorentic 2012 (Archives of Dermatological Research, n=71), Draelos 2006 (Journal of Cosmetic Dermatology, n=71), and the Fitzgerald-class studies. Mechanism data adding to Pickart 1973 isolation. Caveats: cosmetic / GRAS topical only; zero human RCTs for injectable; "anti-aging" outcomes for any delivery route are unestablished; the cosmetic regulatory frame does not support systemic claims; the picker should not purchase it for cosmetic-grade injectable injection even if the bottle is identical.
The community rationale for stacking TB-500 (systemic) and GHK-Cu (topical) is that the two peptides "cover different bases". This framing is structurally wrong: TB-500 has zero human RCTs in any delivery route, GHK-Cu has zero human RCTs for injectable, and the two peptides operate at different non-overlapping mechanisms — the combination is two unproven peptides at unrelated pathways, not receptor-complementary like Sermorelin + Ipamorelin (Sermorelin vs Ipamorelin). Caveats: the pairing stacks regulatory exposure (TB-500 is WADA S0; GHK-Cu cosmetic-grade injectable is unapproved) without an evidence base; the community "stack" framing conflates SCOPE, not mechanism; the buyer should not assume either component "covers" the other's evidence gap.
"Evidence tier" is the most important field in every claim above. Two peptides can share "healing" framing while having radically different evidence behind that framing. The badge colors map to the same four-tier language used across all PeptideDecoded deep-dives:
For deeper context on how to evaluate any peptide claim — peer review, COI checks, red flags, and a 5-question pre-purchase checklist — see How to Verify Peptide Claims and the Editorial Standards page.
This comparison is the synthesis. The full evidence reviews are the underlying references — open either one if you want to evaluate a specific claim, verify a citation, or read the COI disclosure in detail.
Competitive athletes (WADA S0 for TB-500): TB-500 is prohibited at all times under WADA S0 (non-approved substances subcategory). A positive test results in a ban, and there is no Therapeutic Use Exemption (TUE) pathway. GHK-Cu is not WADA-listed but is not a candidate for athletic-performance claims either — the cosmetic / GRAS topical regulatory framing is the registration boundary. The pairing does not change TB-500's WADA status.
Anyone seeking an FDA-approved therapy: neither peptide is approved for any systemic / athletic indication. TB-500's FDA status is narrow (orphan-drug only for corneal / ophthalmic indications); GHK-Cu's FDA status is cosmetic / GRAS topical only — no compounding monograph for either systemic route. Stacking amplifies regulatory exposure without adding evidence.
Anyone needing proven human efficacy: TB-500 has zero human RCTs for any indication in any delivery route as of August 2026. GHK-Cu has human RCTs only for the topical delivery route — injectable is unproven. Community-reported outcomes are not clinical evidence. The TB-500 / GHK-Cu pairing does not "cover" the evidence gap; both peptides have evidence bases restricted to the route they were tested in, with no cross-route transferability.
This comparison page is a research summary, not medical advice. PeptideDecoded does not sell peptides, recommend vendors, provide dosing protocols, or make claims about safety or efficacy for any specific individual.
Work with a qualified physician who can evaluate your full medical history, current medications, and individual risk factors before making any decision about peptides — whether FDA-approved, compounded, or sold as research chemicals.